Zentera Therapeutics is a clinical-stage biopharmaceutical company focused on developing cancer therapeutics in China. Formed by Zentalis Pharmaceuticals to develop cancer therapies in China, Zentera is advancing a pipeline of Zentalis-discovered oncology clinical candidates. Its lead assets include ZN-c3 (a WEE1 inhibitor), ZN-c5 (an oral selective estrogen receptor degrader for ER+/HER2- breast cancer) and ZN-d5 (a BCL-2 inhibitor). The company is led by CEO Dr. Anthony Sun, who is also Chairman and Chief Executive Officer at Zentalis. In April 2021 Zentera raised $75M in a Series B to support advancement of its three clinical candidates and business development for future pipeline additions in China. Zentalis Pharmaceuticals, its parent, is a clinical-stage company focused on discovering and developing small-molecule therapeutics with operations in New York and San Diego.

Total raised

$75M

Funding rounds

1

Latest round

Series B

Latest activity

Aug 2021